H.Res. 928 is a resolution expressing congressional support for "most-favored-nation" drug pricing, which would tie American prescription drug prices to the lowest prices charged in other developed countries. The resolution points out that Americans currently pay significantly higher drug costs than patients in comparable nations—nearly 2.78 times more—and that many Americans skip doses or avoid filling prescriptions due to cost. The resolution affirms support for President Trump's May 2025 executive order directing the administration to lower drug prices to match those in other developed nations and endorses bipartisan legislative efforts aligned with this goal. While this resolution does not create new law or funding requirements, it signals the House's commitment to reducing prescription drug costs through various policy approaches, including Medicare drug price negotiation and promoting market competition. The resolution was introduced in December 2025 and referred to the House Committee on Energy and Commerce.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.